We are already making plans for Scientific Sessions 2019 Nov. 16-18, 2019, in Philadelphia. Be sure to mark your calendars so you can join us to learn about all of the new science that will affect your daily work.
Also, check out the dates for AHA/ASA 2019 specialty conferences.
Archive
Save the date for Scientific Sessions 2019
Attendees rack up steps in Walking Challenge
Attendees at Scientific Sessions 2018 tracked their daily steps and watched them feed into a leaderboard, comparing their steps to leading walkers.
Let’s hack
Smart Socks won the first AHA Rise Above Heart Failure Hackathon during Scientific Sessions 2018. Smart Socks and other teams of five were challenged to brainstorm a non-therapy (non-medicine) innovative solution to optimize heart patient care.
HHS releases second edition of Physical Activity Guidelines for Americans: Q&A with Don Wright, MD, MPH
The U.S. Department of Health and Human Services released the second edition of the Physical Activity Guidelines for Americans.
HHS released the federal government’s first science-based recommendations on physical activity to prevent disease and promote health in 2008.
Highlights of the 2018 Guideline on the Management of Blood Cholesterol
The “2018 Guideline on the Management of Blood Cholesterol” is an update to the 2013 guideline on diagnosing, treating, and monitoring high cholesterol.
REGROUP trial: Major adverse cardiac events results similar for endoscopic vein harvesting compared to open vein harvesting for CABG
There were no significant differences in major adverse cardiac events for endoscopic vein harvesting compared to open vein harvesting for CABG, according to Randomized Endovein Graft Prospective (REGROUP) results presented at Scientific Sessions 2018 in Chicago.
PIONEER-HF: Sacubitril/valsartan reduced cardiovascular biomarker in patients with reduced ejection fraction hospitalized for acute decompensated heart failure
Compared to enalapril, sacubitril/valsartan was associated with a greater reduction in the biomarker N-terminal pro-brain natriuretic peptide and re-hospitalization for heart failure, according to a study presented at Scientific Sessions 2018 in Chicago.
BRIDGE trial suggests quality improvement interventions may increase use of evidence-based therapies
The BRIDGE Cardiovascular Prevention Cluster Randomized Trial found that a multifaceted quality improvement educational intervention significantly increased the use of evidence-based therapies for cardiovascular disease in a low- and middle-income setting.
Results from DECLARE trials show drug may reduce CV death or hospitalizations for HF patients with Type 2 diabetes
The SGLT-2 inhibitor dapagliflozin met one primary composite endpoint with a statistically significant reduction in heart failure hospitalization or cardiovascular death versus placebo, according to results presented in a Late-Breaking Clinical Trial session at Scientific Sessions 2018 in Chicago.
Yoga may have potential for cardiac rehab in low- and middle-income settings
Yoga-based cardiac rehabilitation may have potential in post-myocardial infarction patients compared with enhanced standard care, according to a multicenter randomized controlled trial in India.